Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 5/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21400034 | 0.88 | KCNH2 (0.60) | PTPN1ALDH1A1HSD17B10KCNH2KDM4E | |
| SCHEMBL14578440 | 0.86 | MTNR1A (0.48) | PTPN1ALDH1A1HSD17B10KCNH2KDM4E | |
| SCHEMBL15898858 | 0.83 | PTPN1 (0.47) | PTPN1ALDH1A1HSD17B10KCNH2KDM4E | |
| SCHEMBL15898815 | 0.81 | PTPN1 (0.46) | PTPN1ALDH1A1HSD17B10KCNH2KDM4E | |
| SCHEMBL177538 | 0.81 | MAOB (0.47) | PTPN1ALDH1A1HSD17B10KCNH2KDM4E | |
| SCHEMBL2090916 | 0.81 | PTPN1 (0.46) | PTPN1ALDH1A1HSD17B10KCNH2KDM4E | |
| SCHEMBL7533220 | 0.80 | ALOX15 (0.58) | PTPN1ALDH1A1HSD17B10KCNH2KDM4E | |
| SCHEMBL11582560 | 0.79 | ALDH1A1 (0.55) | ALDH1A1PDE10APOLBTP53MAOB | |
| SCHEMBL10222548 | 0.79 | TP53 (0.59) | ALDH1A1HSD17B10POLBTP53MTNR1A | |
| SCHEMBL4134149 | 0.79 | PTPN1 (0.44) | PTPN1ALDH1A1HSD17B10KCNH2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572910-B2 | Pyridazinone aldose reductase inhibitors | PFIZER, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1491541-B1 | Pyridazinone aldose reductase inhibitors | PFIZER PROD INC (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1491540-B1 | Intermediates useful for the synthesis of pyridazinone aldose reductase inhibitors | PFIZER PROD INC (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20050113381-A1 | Pyridazinone aldose reductase inhibitors | MYLARI BANAVARA L (US) | 2005-05-26 | — | — | US | disclosed |
| US-6849629-B2 | Heteroaromatic substituted sulfonyl or sulfoxide or thio-pyridazinone derivatives, useful for treating diabetic complications and cardiovascular disorders | PFIZER, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-20050004124-A1 | THERAPIES RELATING TO COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | MYLARI BANAVARA L (US) | 2005-01-06 | — | — | US | disclosed |
| EP-1373259-B1 | PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS | PFIZER PROD INC (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040198740-A1 | Therapies relating to combinations of aldose reductase inhibitors and cyclooxygenase-2 | PFIZER INC | 2004-10-07 | — | — | US | disclosed |
| CN-1505514-A | Combination of aldose reductase inhibitors with cyclooxygenase-2 inhibitors | �Ʒ� | 2004-06-16 | — | — | CN | disclosed |
| EP-1392310-A1 | COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | Pfizer Products Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-1373259-A1 | PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS | Pfizer Products Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030162784-A1 | Pyridazinone aldose reductase inhibitors | MYLARI BANAVARA L (US) | 2003-08-28 | — | — | US | disclosed |
| US-6579879-B2 | Pyridazinone aldose reductase inhibitors | PFIZER INC | 2003-06-17 | — | — | US | disclosed |
| WO-2002087584-A1 | COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002079198-A1 | PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-10-10 | — | — | WO | disclosed |
| US-20020143017-A1 | Pyridazinone aldose reductase inhibitors | MYLARI BANAVARA L (US) | 2002-10-03 | — | — | US | disclosed |
| EP-0000128-A1 | Sulfamoylaryl ketones, process for their preparation and their use as medicaments | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113381-A1 | Pyridazinone aldose reductase inhibitors | SLC5A1, ALDOA, AKR1B1 | PTPN1 1807/4885ALDH1A1 30/4885HSD17B10 220/4885 |
| US-20030162784-A1 | Pyridazinone aldose reductase inhibitors | SLC5A1, ALDOA, AKR1B1 | PTPN1 1807/4885ALDH1A1 30/4885HSD17B10 220/4885 |
| US-20020143017-A1 | Pyridazinone aldose reductase inhibitors | SLC5A1, AKR1B1, AKR1D1 | PTPN1 1843/4885ALDH1A1 27/4885HSD17B10 183/4885 |
| US-20050004124-A1 | THERAPIES RELATING TO COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | ALDOA, AKR1B1, ALDH2 | PTPN1 2455/4885ALDH1A1 30/4885HSD17B10 125/4885 |
| US-20040198740-A1 | Therapies relating to combinations of aldose reductase inhibitors and cyclooxygenase-2 | ALDOA, ALDH2, AKR1B1 | PTPN1 2672/4885ALDH1A1 30/4885HSD17B10 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.